<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01344317</url>
  </required_header>
  <id_info>
    <org_study_id>Nationalbankprojekt Nr.13660</org_study_id>
    <nct_id>NCT01344317</nct_id>
  </id_info>
  <brief_title>The Effect of Stimulating Substances on Brain Activity of Preterm Infants</brief_title>
  <official_title>The Effect of Stimulating Substances on Brain Activity Measured by Amplitude-integrated EEG and Long-term Neurodevelopmental Outcome of Preterm Infants Born Below 30 Weeks of Gestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Methylxanthines and doxapram have been widely used for the treatment of apneas&#xD;
      of prematurity. Both substances have effects on the central nervous system. While there are&#xD;
      data available concerning the use of caffeine (the methylxanthine used at our NICU) even&#xD;
      proposing a positive effect on neurodevelopmental outcome of very preterm infants, there are&#xD;
      data which suggest a negative effect of the central stimulants doxapram on longterm outcome&#xD;
      in this group of infants. Nevertheless concerning both medications only few studies have been&#xD;
      published and only scarce data are available concerning the effect of these medications on&#xD;
      brain activity of very preterm infants until now.&#xD;
&#xD;
      The aim of this study: is the assessment of the effect of stimulating substances on brain&#xD;
      activity of preterm infants born below 30 weeks of gestation and their longterm&#xD;
      neurodevelopmental follow-up.&#xD;
&#xD;
      Methods: This study is a prospective study including preterm infants born below 30 weeks of&#xD;
      gestational age. Brain activity is measured by one-channel amplitude-integrated EEG (aEEG).&#xD;
      The first aEEG measurement is performed without caffeine and/or doxapram medication. At least&#xD;
      one hour of brain activity is registrated. The second measurement is done at least 24 hours&#xD;
      after the start of caffeine and/ or doxapram treatment.&#xD;
&#xD;
      The percentage of different background patterns, the occurrence and duration of&#xD;
      sleep-wake-cycling, and the occurrence and duration of seizures is assessed and analysed.&#xD;
      Neurodevelopmental outcome is assessed at one and two years of corrected age by assessment of&#xD;
      the Bayley Scales of Infant Development II and standardized clinical neurological&#xD;
      examination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Apneas of Prematurity</condition>
  <arm_group>
    <arm_group_label>Caffeine group</arm_group_label>
    <description>Premature infants below 30 weeks of gestation who receive Caffeine treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caffeine and Doxapram group</arm_group_label>
    <description>Premature infants below 30 weeks of gestation who receive Caffeine and Doxapram treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group with no treatment</arm_group_label>
    <description>Premature infants below 30 weeks of gestation with no stimulating treatment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Preterm infants born below a gestational age of 30 weeks&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        see above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  intraventricular hemorrhage&#xD;
&#xD;
          -  posthaemorrhagic hydrocephalus&#xD;
&#xD;
          -  cerebral infection&#xD;
&#xD;
          -  cerebral malformation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Weeks</minimum_age>
    <maximum_age>30 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manfred Weninger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Pediatrics and Adolescent Medicine, Neonatology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>April 27, 2011</study_first_submitted>
  <study_first_submitted_qc>April 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2011</study_first_posted>
  <last_update_submitted>October 30, 2015</last_update_submitted>
  <last_update_submitted_qc>October 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Christine Czaba</investigator_full_name>
    <investigator_title>Dr.med.univ.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

